Highlights of weekly biotech stock moves

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) was off Rs9.10 to Rs282.45 last week on India's National Stock Exchange after the Drugs Controller General of India approved Alzumab itolizumab to treat chronic plaque psoriasis. The company plans to launch the product this year.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was up $0.24 to $2.97 last week after announcing partner Japan Tobacco Inc. (Tokyo:2914; Osaka:2914) submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for Zerenex ferric citrate to treat hyperphosphatemia in patients with chronic kidney disease (CKD). The submission triggered a $7 million payment to Keryx...